Cullinan Oncology
Latest round
- Series C
Last raised
- Dec 2020
Total raised
- $380M
Investors
- 15
About Cullinan Oncology
, Cullinan Oncology, LLC operates as a developer of therapeutics for the treatment of cancer. Park Vale Capital, Baupost Group, Eventide Asset Management, and Logos Capital fully exited their stake in Cullinan Oncology, LLC, for an undisclosed amount. The firm trades on NASDAQ under the Ricker symbol CGEM. The company provides a wide range of therapeutic products, such as monoclonal antibodies, small molecules, and bispecific antibodies for oncology and autoimmune indications.
Who invested in Cullinan Oncology
15 investors across 3 rounds
See all investors in Cullinan Oncology
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Cullinan Oncology
Who invested in Cullinan Oncology?
Cullinan Oncology has 15 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Cullinan Oncology raised?
Cullinan Oncology has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Cullinan Oncology last raise money?
Cullinan Oncology's most recent round on record is a Series C, in Dec 2020.
What does Cullinan Oncology do?
, Cullinan Oncology, LLC operates as a developer of therapeutics for the treatment of cancer.
Where is Cullinan Oncology headquartered?
Cullinan Oncology is headquartered in Cambridge, US.
Which VCs invest in companies like Cullinan Oncology?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Cullinan Oncology's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series C
Raising like Cullinan Oncology? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.